| United States Patent |
5,162,037 |
| Whitson-Fischman |
November 10, 1992 |
A method for treating pathogenic conditions of the human body by preparing a
homeopathic mixture of at least one herb, herbal extract or other compound
exhibiting therapeutic properties, adding a magnetically permeable substance to
the mixture if necessary, magnetizing the resulting mixture to impart a
substantially unipolar magnetic charge on the mixture and administering the
magnetized mixture through one or more specific acupuncture points associated
with producing a desired response to the particular condition being treated. The
invention is also directed to the treatment of various diseases through the
oral, auricular, topical or injectable administration of magnetically influenced
homeopathic medicaments.
| Inventors: |
Whitson-Fischman; Walter (New York,
NY) |
| Assignee: |
Whitson Laboratories, Inc. (New York,
NY) |
| Appl. No.: |
696759 |
| Filed: |
May 7, 1991 |
| U.S. Class: |
600/12; 600/15; 128/907 |
| Intern'l Class: |
A61N 002/00 |
| Field of Search: |
600/9,12,15 128/907 |
References Cited [Referenced
By]
U.S. Patent Documents
| 2671451 |
Mar., 1954 |
Bolger |
128/260. |
| 4501726 |
Feb., 1985 |
Shroder et al. |
424/1. |
| Foreign Patent Documents |
| 0000667 |
Feb., 1979 |
EP. |
|
| 0035932 |
Sep., 1981 |
EP. |
|
| 0208362 |
Jan., 1987 |
EP. |
|
| 1467974 |
Jan., 1969 |
DE. |
|
| 1492136 |
Sep., 1969 |
DE. |
|
| 2062080 |
Jul., 1971 |
DE. |
|
| 3634121 |
Nov., 1987 |
DE. |
|
| 2258839 |
Aug., 1975 |
FR. |
|
| 60032716 |
Jul., 1983 |
JP. |
|
| 61-115015 |
Jun., 1986 |
JP. |
|
| 63-159313 |
Jul., 1988 |
JP. |
|
| 1147411 |
Mar., 1985 |
SU |
600/12. |
| 1335297 |
Sep., 1987 |
SU |
600/9. |
| 1264511 |
Feb., 1972 |
GB. |
|
| WO78/00005 |
Dec., 1978 |
WO. |
|
Other References
|
Orekhov et al., "Prevention . . . Aspirin", The Lancet,
Sep. 5, 1987. |
Primary Examiner: Cohen; Lee S.
Attorney, Agent or Firm: Haug; Edgar H. Kilcoyne; John M.
Parent Case Text
FIELD OF THE INVENTION
This application is a continuation-in-part of application Ser. No. 540,295,
filed Jun. 19, 1990, abandoned, which in turn is a continuation of
application Ser. No. 176,731, filed Apr. 1, 1988, abandoned.
Claims
1. A method for treating pathogenic conditions of the human body comprising
the steps of:
preparing a mixture of at least one herb, herbal extract or other compound
having therapeutic properties to which a particular condition being treated
is responsive;
adding a magnetically permeable substance to the mixture if necessary;
magnetizing the resulting mixture in a magnetic field during delivery to
impart a substantially unipolar magnetic charge on said mixture; and
administering the magnetized mixture through one or more specific
acupuncture points of the body which are associated with producing a desired
response to the particular condition being treated.
2. The method of claim 1 wherein the mixture is magnetized in a magnetic
field of less than ten gauss.
3. The method of claim 1 wherein the magnetized mixture is topically
administered to the body.
4. The method of claim 3 wherein a therapeutic amount of the magnetized
mixture is placed over at least one pair of bilateral acupuncture points on
the surface of the body.
5. The method of claim 4 wherein the mixture is magnetized by placing a
source of magnetic flux in proximity to the mixture while it is placed over
the bilateral acupuncture points on the surface of the body.
6. The method of claim 1 wherein the magnetized mixture is injectably
administered to the body.
7. The method of claim 6 wherein a therapeutic amount of the magnetized
mixture is injected into at least one pair of bilateral acupuncture points
of the body.
8. The method of claim 1 wherein the magnetized mixture is auricularly
administered to the body.
9. The method of claim 8 wherein a therapeutic amount of the magnetized
mixture is impregnated into metal rods inserted into a device fitted to be
placed over the ear, the metal rods being located in said device such that
the magnetized mixture is in contact with at least one auricular acupuncture
point when the device is placed over the ear.
10. The method of claim 1 wherein the magnetized mixture is orally
administered to the body.
11. The method of claim 10 wherein a therapeutic amount of the magnetized
mixture is administered to acupuncture points in the mouth by means of an
oral delivery device which is magnetically transparent and permeable
comprising a rod portion connected to a porous ball portion, said rod
portion being capable of accepting and holding a magnetic charge, and said
ball portion being impregnated with an effective amount of said mixture,
wherein said rod portion of the device is magnetized so that the desired
charge is at the ball portion, and wherein the patient places the ball
portion of the device under the tongue to influence the acupuncture points.
12. A method for the treatment of conditions of the human body including
injuries, illnesses, pathogenic diseases, allergies and chemical and
hormonal imbalances, the method comprising the administration of a
combination of oral, injectable and topical forms of a therapeutic amount of
a magnetized solution containing a solute of one or more therapeutic herbs
or herbal extracts or other compounds having properties to which the
particular condition being treated is responsive, the solute being dissolved
in a vehicle, where the vehicle for the oral and topical form is a mixture
of 99+% alcohol, and the vehicle for the injectable form is a mixture of
99+% alcohol diluted with sterile isotonic saline, together with a
magnetically permeable, non-toxic substance if necessary; and wherein the
oral form is impregnated into a solid placed in the mouth to release the
magnetized mixture contained therein, thereby stimulating acupuncture points
in the mouth; wherein the topical form is also impregnated into a solid and
affixed as a transdermal patch to at least one suitable acupuncture point;
and wherein the injectable form is injected into at least one specific
acupuncture point of the body related to the part of the body or the
condition being treated; the oral, topical and injectable treatments being
administered in appropriate dosages for a sufficient period of time
depending on the severity of the condition and the response of the patient
being treated, with provision for a further period of maintenance treatments
of different dosage and frequency of administration where symptoms of the
condition persist.
13. The method of claim 12 wherein the condition being treated is traumatic
injury to one or more joints, muscles, tendons and ligaments and the solute
of the magnetized solution comprises an effective amount of one or more
herbs or extracts selected from the group consisting of Arnica Montana,
Symphytum officianalis, Moschus moschiferous, Cow bezoar, Pupalia geniculata,
Snake's gall, Rhus Toxicum, Germanuim dioxide, Plantago asiatica, Causticum,
Helianthemum canadense, Ornithogalum umbellatum, Clematis crispa, Impatiens
pallida, Prunus Cerasus and pineal gland.
14. The method of claim 12 wherein the oral dosage is a metal rod and sphere
impregnated with a solution having a homeopathic potency of 30.times.,
administered initially as one rod and sphere per day, reduced to one every
other day and finally to once per week over the course of treatment; wherein
the topical dosage is a transdermal patch, impregnated with a solution
having a homeopathic potency of 30.times., placed over at least one
acupuncture point two times per week for a first phase of treatment and once
per week on successive weeks over a maintenance phase of treatment; wherein
the injectable dosage is an injection of 0.2 cc per acupuncture point of the
injectable solution having a homeopathic potency of 30.times., administered
to the acupuncture points and related local acupuncture points for the
specific injured member being treated, the injections being given initially
2 times per week for a first phase of treatment and once per week on
successive weeks over the balance of a therapeutic phase as well as a
maintenance phase of treatment; and wherein the duration of the oral,
topical and injectable modes of treatment is from about 12 weeks, followed
by a period of maintenance for as long as symptoms of the condition persist.
15. The method of claim 12 wherein the condition being treated is
hypothyroidism and the solute of the magnetized solution comprises an
extract of thyroid gland.
16. The method of claim 15 wherein the injectable and topical dosages are
administered bilaterally to each of the two LI-11 acupuncture points 2 times
per week for the first week of treatment and once per week on successive
weeks over the course of treatment; and wherein the duration of the oral,
topical and injectable modes of treatment is six weeks, followed by a period
of maintenance of several weeks for as long as the symptoms of the condition
persist.
17. The method of claim 12 wherein the condition being treated is one or
more of pre-menstrual syndrome, menopause and reproductive hormonal
imbalance in female human beings and the solute of the magnetized solution
comprises the herb Angelica sinensis or an extract thereof and an extract of
pineal gland.
18. The method of claim 15 wherein the injectable and topical dosages are
administered bilaterally to each of the two LI-11 acupuncture points from 1
to 2 times per week for the first week of treatment and once per week on
successive weeks over the course of treatment; and wherein the duration of
the oral, topical and injectable modes of treatment is from 4 to 8 weeks,
followed by a period of maintenance of several weeks for as long as the
symptoms of the condition persist.
19. The method of claim 12 wherein the condition being treated is emotional
depression and tension, and the solute of the magnetized solution comprises
one or more herbs or herbal extracts selected from the group consisting of
Helianthemum canadense, Ornithogalum umbellatum, Clematis crispa, Impatiens
pallida, Prunus cerasus, Valeriana officinalis and pineal gland.
20. The method of claim 17 wherein the injectable and topical dosages are
administered bilaterally to the SP-6 acupuncture points a total of four to
six times, followed by a period of maintenance of several weeks for as long
as symptoms of the condition persist.
21. The method of claim 12 wherein the condition being treated is a
reduction in the body's natural immune system and the solute of the
magnetized solution comprises one or more herbs or extracts selected from
the group consisting of Panex ginseng, Astragalus membranaceous, Snake
venom, thymus gland, Rubia cordifolia and pineal gland.
22. The method of claim 20 wherein the injectable and topical dosages are
administered bilaterally to one of the following pairs of acupuncture
points: HE-5, HE-6 and HE-7, given 2 times per week for the first week of
treatment and once per week on successive weeks over the course of
treatment; and wherein the duration of the oral, topical and injectable
modes of treatment is 6 weeks, followed by a period of maintenance of
several weeks for as long as symptoms of the condition persist.
23. The method of claim 22 wherein the injectable and topical dosages are
administered bilaterally to each of the two LI-4 acupuncture points 2 times
per week for the first week of treatment and once per week on successive
weeks over the course of treatment; and wherein the duration of the oral,
topical and injectable modes of treatment is 6 to 8 weeks, followed by a
period of maintenance of several weeks for as long as the symptoms of the
condition persist.
24. The method of claim 12 wherein the condition being treated is
hypoglycemia and the solute of the magnetized solution comprises a mixture
of sulfur and glycerin.
25. The method of claim 24 wherein the injectable and topical dosages are
administered bilaterally to each of the two ST-36 acupuncture points, given
2 times per week for the first week of treatment and one per week on
successive weeks over the course of treatment; and wherein the duration of
the oral, topical and injectable modes of treatment is from 6 to 8 weeks,
followed by a period of maintenance of several weeks for as long as symptoms
of the condition persist.
26. The method of claim 12 wherein the condition being treated is a general
or localized bacterial infection of the body, and the solute of the
magnetized solution comprises one or more herbs or extracts selected from
the group consisting of Seniccio scandens, Scutellaria baicalensis, Magnolia
officinalis, Lonicera japonica, Andrographis paniculata, Centella asiatica
minor, Leptotaenia multifida, Moschus moschiferous, Cow bezoar, Pupalia
geniculata, Snake's gall and pineal gland.
27. The method of claim 26 wherein the injectable and topical dosages have a
homeopathic potency of 30.times., and are administered bilaterally to each
of the two IL-11 acupuncture points, given 2 times per weeks for the first
week of treatment and one per week on successive weeks over the course of
treatment; and wherein the duration of the oral, topical and injectable
modes of treatment is 6 to 12 weeks depending on the pathogen being treated,
followed by a period of maintenance of several weeks for as long as the
symptoms of the condition persist.
28. The method of claim 12 wherein the condition being treated is a general
virus infection of the body and the solute of the magnetized solution
comprises one or more herbs or extracts selected from the group consisting
of Centella asiatica minor, Pyrrosia lingua, Hypericum perfoliatum,
Trichosanthes Kirilowii, Artemasia apiacea and pineal gland.
29. The method of claim 28 wherein the injectable and topical dosages have a
homeopathic potency of 30.times., and are administered bilaterally to each
of the two TW-5 acupuncture points, given 1 or 2 times per week for the
first week of treatment and once per week on successive weeks over the
course of treatment; and wherein the duration of the oral, topical and
injectable modes of treatment is from 8 to 12 weeks, followed by a period of
maintenance of several weeks for as long as symptoms of the condition
persist.
30. The method of claim 12 wherein the condition being treated is a cold
caused by the rhino-virus or influenza and the solute of the magnetized
solution comprises one or more herbs or extracts selected from the group
consisting of Lonicera confusa, Chrysanthemum indicum, Vitex negundo, Evodia
lepta, Ilex asprella, Menthol crystal, Baphicacanthus cusia, Centella
asiatica minor and pineal gland.
31. The method of claim 30 wherein the injectable and topical dosages are
administered bilaterally to each of the two TW-5 acupuncture points, given 2
times per week for the first week of treatment and once per week on
successive weeks over the course of treatment; and wherein the duration of
the oral, topical and injectable modes of treatment is three weeks, followed
by a period of maintenance of several weeks for as long as symptoms of the
condition persist.
32. The method of claim 12 wherein the condition being treated is one or
more of hay fever and airborne allergies, and the solute of the magnetized
solution comprises one or more herbs or extracts selected from the group
consisting of Gentiana luta, Citrus aurantium, Tanacetum vulgare, Cnicus
benedictus, Menyanthes trifoliata, Grindelia robusta, Ephedra sinica,
Centipeda minima, pineal gland and Centella asiatica minor.
33. The method of claim 32 wherein the injectable and topical dosages are
administered bilaterally to each of the two PE-6 acupuncture points or the
auricular lung point, given 2 times per week for the first week of treatment
and once per week on successive weeks over the course of treatment; and
wherein the duration of both the oral and injectable modes of treatment is
from 2 to 4 weeks, followed by a period of maintenance of several weeks for
as long as the symptoms of the condition persist.
34. The method of claim 12 wherein the condition being treated is one or
more of local and systemic fungus and yeast infections, and the solute of
the magnetized solution comprises one or more herbs or extracts selected
from the group consisting of Malaleuca alternifolio, Centella asiatica
minor, citrus seed, Tacoma conspicus and pineal gland.
35. The method of claim 34 wherein the injectable and topical dosages are
administered bilaterally to the SP-6 acupuncture point, given 2 times per
week for the first week of treatment and once per week on successive weeks
over the course of treatment; and wherein the duration of the oral, topical
and injectable modes of treatment is from 6 to 12 weeks, followed by a
period of maintenance of several weeks for as long as symptoms of the
condition persist.
36. The method of claim 12 wherein the condition being treated is
infestation with intestinal parasites and the solute of the magnetized
solution comprises one or more herbs or extracts selected from the group
consisting of Osbeckia chinensis, Pulsattila chinensis, Punica granatum,
Acalpha australis, Cephaelis ipecacuanha, Picrasma ailanthoides, Asarum
sieboldi, Brucea javanica, Magnolia officinalis, Artemisia apiacea, Dichroa
febrifuga, Centella asiatica minor, citrus seed and pineal gland.
37. The method of claim 36 wherein the injectable and topical dosages are
administered bilaterally to the ST-36 and ST-37 acupuncture points which are
used alternately and treatments are given 2 times per week for the first
week and once per week on successive weeks over the course of treatment; and
wherein the duration of both the oral and injectable modes of treatment is
from six to eight weeks, followed by a period of maintenance of several
weeks if required.
38. The method of claim 12 wherein the condition being treated is acute or
chronic muscular and joint pain and the solute of the magnetized solution
comprises one or more herbs or extracts selected from the group consisting
of Arnica Montana, Symphytum officianalis, Moschus moschiferous, Cow bezoar,
Pupalia geniculata, Snake's gall, Rhus Toxicum, Germanuim dioxide, Plantago
asiatica, Causticum, Helianthemum canadense, Ornithogalum umbellatum,
Clematis crispa, Impatiens pallida, Prunus Cerasus and pineal gland.
Description
This invention relates to homeopathic medicaments and methods for the
treatment of illness and injury in human beings using such homeopathic
medicaments.
More particularly, the invention relates to homeopathic methods of treatment
of conditions including illnesses, pathogenic diseases, allergies, chemical
and hormonal imbalances, addictive chemical dependencies, and physical
injuries to the human body. The methods of treatment include oral, topical,
auricular and injectable forms of homeopathic formulations which are
magnetically treated or influenced during administration to a patient
through specific acupuncture points.
BACKGROUND OF THE INVENTION
Homeopathy is an
ancient healing art and forms a vital part of medical therapy. The practice
of homeopathy is
widespread, particularly in eastern cultures and many European countries.
Homeopathic medicine teaches the use of natural based remedies and, as such,
provides an alternative to traditional allopathic medicine which relies
heavily on the use of petrochemical based pharmaceuticals. There has been a
large increase in interest in homeopathic medicine in the United States in
recent years due, in large part, to a growing disenchantment with allopathic
medications and the complications and side effects arising from their use.
Frequently, the administration of allopathic medications results in serious
side effects more deleterious to the patient than the basic condition being
treated. Today, more and more individuals are looking for a gentler, safer
path to good health free of the risks and side effects associated with
traditional allopathic medicines. Furthermore, such medicines are often
prohibitively expensive, particularly for patients who are indigent or
elderly.
Homeopathic remedies, on the other hand, use pharmaceutical preparations
based on the use of herbs or herbal extracts. Homeopathic remedies function
in a totally different manner than chemical-based pharmaceuticals in that
they do not require administering high concentrations of active ingredients
to produce the desired effects. Traditional allopathic pharmaceuticals can
be thought of as working quantitatively, that is, the results achieved are
generally proportional to the potency and frequency of the dosage
administered. By comparison, homeopathic pharmaceuticals can be thought of
as working qualitatively in that even the minutest quantities of their
active ingredients produce a therapeutic effect by inducing natural body
mechanisms to return to their proper level of activity characteristic of a
healthful or uninjured state. Homeopathic remedies function by inducing
natural body mechanisms and processes to return to their optimum healthful
level of operation, that is, their natural biological "set
points".
Through our modern understanding of genetics, each bodily member and process
is seen as the result of codes programmed into each individual cell.
Homeopathic medicine seeks to utilize natural substances, particularly
herbs, to induce naturally and gently the body to restore its equilibrium,
that is, for all function and processes to return to their set points.
Homeopathic medicine looks upon illness and disease as being a state of
disequilibrium from the body's optimal set points. A fundamental precept of
homeopathic medicine is that a small force or stimulating agent can produce
disproportionally greater results, if optimally and effectively applied.
Thus, proper administration of a small quantity of a homeopathic medicine
can have a large effect in restoring the body to its proper state of
equilibrium.
A further advantage of homeopathic medicaments is that they are relatively
inexpensive as compared to traditional chemical-based pharmaceuticals.
Another fundamental precept in the formulation of homeopathic
pharmaceuticals is that repetitive dilution from an original concentrate
does not diminish efficacy of the formulation. Thus, large quantities of
homeopathic pharmaceuticals can be prepared from a relatively small amount
of starting solution. Further, the starting ingredients themselves are
natural and relatively inexpensive. The formulation of solutions of
homeopathic pharmaceuticals is also a relatively simple process.
Additionally, homeopathy
utilizes various medicaments in extremely dilute form. For example, all the
medicines used in accordance with the present invention are generally used
at a potency of 30.times. which is a 1-10 dilution taken to the 30th power.
One of the long standing adjustments that was made long ago was a
determination of exactly what materials are suitable as diluents. The list
is small and primarily restricted to 200 proof Ethyl alcohol, distilled
water, sugar and milk sugar. With the possible exception of distilled water,
none of these are really totally inert. All the others contribute some
identity of their own. As a matter of fact, both sugar and milk sugar are
listed as medicants (when in homeopathic dilution) in the homeopathic
materia medica.
One example of a homeopathic medicament is extract of pineal gland. As noted
in the technical text, "The Pineal Gland" by Russel J. Reiter
(Raven Press, N.Y. 1984), the pineal gland occupies a unique physiological
niche. Its function has been described as being "the regulator of
regulators". The primary action of the pineal gland is believed to be
to "govern or restrict the production and/or the secretion of hormones
from other endocrine glands."
Since conventional allopathic medications utilize massive chemical
intervention as the modus operandi with the actual destruction of the
offending pathogen as the ultimate goal, there is little possibility for an
interface between the powerful but very subtle activity of the pineal gland
and the mighty action of petrochemicals. Homeopathy,
however, since it is a vastly more subtle form of medication, appears to be
able to intensify the actions of the pineal.
To make the base tincture of the pineal gland, one portion of a freeze dried
animal sample of the gland itself is comminuted and then macerated in pure
ethanol for ten days with daily agitation. At the end of this time, the
extract is filtered. An equal sample of the same material is added to
distilled water, brought to a slow simmer and maintained at this point while
it is allowed to steep for one hour. At the end of this time, the water
extract is also filtered.
Equal amounts of the alcohol and the water extracts are combined to form the
base tincture.
In contrast, the manufacture of traditional chemical-based pharmaceuticals
generally involves a complicated and costly chemical manufacturing process.
Moreover, because the effectiveness of such traditional chemical-based
pharmaceuticals resides in the potency of the formulation administered,
dilution of the pharmaceutical to a lower potency results in reduced
effectiveness. Generally, all such chemical-based pharmaceuticals must be
formulated at or near the concentration level or potency at which they will
ultimately be administered. Thus, in order to produce large quantities of a
pharmaceutical, proportionately large manufacturing facilities are required,
which only further adds to the expensiveness of the chemical-based
pharmaceuticals utilized in classical allopathic medicine.
Another ancient and long accepted healing art is acupuncture which is
believed to have originated in the Orient. Acupuncture involves the relief
of symptoms and the cure of illness and injury by the controlled stimulation
of points on the human body which regulate or interact with the functioning
of specific organs or bodily members to which the acupuncture points are
related.
Over the many years that acupuncture has been practiced, specific points on
the human body have been determined which regulate or interact with the
functioning of all bodily members and processes. Thus, the appropriate
points for stimulation for any given condition are known to skilled
practitioners in the art.
One particular acupuncture treatment system developed in Japan by Dr. Yoshio
Manaka is based on a conception of the human body as encompassing two basic
systems, an energetic system and an informational system. The energetic
system utilizes the greater portion of energy in the body. The informational
system controls the energetic system and response to both external and
internal stimuli. Acupuncture is viewed as a therapeutic modality which
interacts with and regulates the body's informational system. By influencing
the informational system, large changes can be induced with minimal
stimulation while allowing the body to function as naturally as possible
while its processes are gradually restored to their equilibrium set points.
A recent development in methods of medical treatment has been the discovery
of the therapeutic properties of magnetic and electro-magnetic fields and
their use in the treatment of illness and injury. Modern science has
demonstrated that all living beings exhibit an electro-magnetic field about
them. Homeopathic medicine teaches that illness and injury create
disturbances to the body's natural electro-magnetic fields. The
administration of therapeutic fields restores the body's natural fields to
their equilibrium levels. The therapeutic effects of the application of
pulsed magnetic fields in the treatment of traumatic injuries to limbs,
muscles, tendons, bones and the like, as well as in the treatment of illness
such as arthritis, is well-known in the art of medical science.
The human body's susceptibility to magnetic fields is due in large part to
the electrolytic properties of many of the chemical constituents of the
body. All electrolytic substances are capable of conducting an electric
current, and whenever an electric current is flowing a magnetic field is
created. The greater the electrolytic properties of the substance, the
greater is its conductivity and therefore the greater the resulting magnetic
field created during current flow.
The body generates a magnetic field of its own due partly to the presence of
iron-carrying charged particles flowing in the blood stream. Other
electrolytic substances in the body such as potassium and sodium, in ionic
form, are present in substantial amounts and contribute to the body's
overall bioelectric/biomagnetic field. It is well known that blood cells are
readily polarized when placed in a magnetic field due to the high iron
concentration in the blood. Under certain conditions, magnetic fields alter
the orientation of blood cells and induce changes in the biological
reactions in which they participate, thereby modifying the probability of
chemical bond formation.
Human blood is very slightly alkaline with respect to body cells which are
more acidic. Magnetic fields can be used to induce reactions which restore
the pH of the blood.
For example, in a condition prompted by over-acidity of the blood, that is,
one characterized by a low pH, application of magnetic field energy
emanating from the north pole of a magnet, which, by convention, is
considered to be negative, and which, homeopathically, is considered to be
alkaline, helps to restore the blood to its normal pH level.
It has also been shown that the blood's leucocyte count is influenced by
magnetic fields. The number of leucocytes in the blood increases depending
on prevailing magnetic field conditions.
Therapeutic treatments utilizing magnetic energy operate to produce two
curative effects. Therapeutic magnetic fields produce a treatment component
which in the case of traumatic physical injury causes a reduction in
swelling, a reduction of edema, a draining of fluid build-up due to
inflammation and a desensitization to pain.
Therapeutic magnetic energy fields also produce a stimulating component
which in the case of traumatic physical injury dilates blood vessels and
increases blood circulation, disperses fluid build-up due to inflammation,
and strengthens and promotes the healing of damaged tissue.
The application of pulsed magnetic energy has been observed to cause
transcutaneous electrical neural stimulation and contributes to the
reduction of chronic pain by causing the release of natural pain relieving
substance at the spinal cord level and by causing the release of endorphins
and ACTH at the pituitary gland level.
As a result of research into the fields of homeopathic pharmaceutical
medicine, acupuncture and biomagnetic therapy, a new modality of medical
treatment has been developed which combines the features of all three of the
above treatment methods in a novel way. Accordingly, a new and unique method
of medical treatment has been discovered which is more efficacious than any
of the three methods individually as described above.
OBJECTS OF THE INVENTION
Accordingly, a primary object of the present invention is to disclose a new
modality of medical therapy which utilizes aspects of homeopathic
pharmaceutical therapy, acupuncture therapy and biomagnetic therapy, in
combination.
A further object of the invention is to devise a full range of modes of
administration of magnetically influenced homeopathic remedies, including
topical, injectable, auricular and oral forms.
A further object of the invention is to provide particular homeopathic
pharmaceutical formulations for the treatment of specific illnesses,
physical injuries and other chemical and hormonal disequilibrium conditions
of the human body with precisely determined acupuncture sites to which the
homeopathic pharmaceutical remedies are to be applied in the treatment of
each specific condition.
A further object of the invention is to provide appropriate means for
inducing the biomagnetic field in the homeopathic pharmaceutical remedy for
each form of administration.
SUMMARY OF THE INVENTION
The present invention is directed to a method of treatment of human illness
and injury by administering to the patient homeopathic medicaments through
selected acupuncture points stimulated by a controlled magnetic field. A
very broad spectrum of human illness can be effectively treated by
homeopathic medicament of the instant invention through selection of the
appropriate homeopathic remedy, preparation of a mixture of the homeopathic
remedy and a magnetically permeable component and magnetization of the
resulting mixture during administration to the patient through specific
acupuncture sites.
Various embodiments of the invention include administering therapeutic
amounts of the magnetic mixture in oral, injectable, topical and auricular
forms. Further, depending upon the condition being treated, the dosage and
frequency of administration will vary. In a particularly preferred
embodiment, the patient is administered with a regimen of oral, transdermal
and injectable dosages.
BRIEF DESCRIPTION OF THE DRAWINGS
Aspects of the present invention are illustrated by the accompanying
drawings in which:
FIG. 1 shows a preferred embodiment of an oral delivery vehicle for the
administration of homeopathic medicaments;
FIG. 2 shows an embodiment for the topical administration of a homeopathic
medicament; and
FIG. 3 shows a preferred embodiment for imparting a magnetic field to the
injectable form of the homeopathic medicaments; and
FIG. 4 shows a cross-sectional view through a mold of an ear, with pins
inserted therein, for the auricular administration of a homeopathic
medicament.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION
The homeopathic medicaments of the present invention, when administered
through specific acupuncture sites, have demonstrated remarkable efficacy in
the treatment of a wide range of afflictions, many of which have no known
cure in the realm of allopathic medicine. Effective delivery systems for
these homeopathic formulations have been devised including topical,
injectable, auricular and oral forms.
In accordance with the teaching of the present invention, the homeopathic
medicament, when administered as an injectable, is first carefully mixed
with an effective amount of a magnetically permeable ingredient. Although
numerous compounds are suitable, it has been found that ferrous gluconate is
particularly effective. The herb-based homeopathic medicament is then
prepared for administration to the patient depending upon the specific
delivery system used. During administration to the patient, the medicament,
whether or not it is mixed with a magnetically permeable ingredient, is
charged or influenced by a magnetic field which imparts a unipolar charge to
the medicament as it enters the body through a pre-selected acupuncture
point. Since a magnet has two poles, to effect a unipolar charge to the
medicament, the poles of the delivery devices are separated. The medicament
and the body are only exposed to one pole. The other pole is outside of, or
away from, the body. In this way, the medicament is exposed to the influence
of only one pole. Such application of a magnetic charge at, or in close
proximity to, the acupuncture site is believed to stimulate or activate the
acupuncture site thereby enhancing the therapeutic efficacy of the
medicaments being administered.
Acupuncture points can be stimulated with heat, electricity, ultrasound,
laser beams, mechanical vibration, etc. However, stimulation by magnetism
has been found to be one of the most effective, and yet, at the same time,
is one of the most benign.
Particularly effective results have been achieved when applying relatively
small levels of magnetic charge in the range of 1 to 10 gauss to the
medicament as it is being administered into the acupuncture point. Such low
levels of magnetic flux can aptly be described as homeopathic. It has
further been found that the most effective acupuncture sites are located in
the arms and legs below the elbow and knee, respectively. These points are
commonly referred to as "command points" and are well known to
those skilled in the art.
Having described the invention in its most fundamental terms, the various
forms of administration of medicaments will now be described in detail.
Reference is made to the accompanying figures where appropriate.
One delivery system used is by injection. The formulation dosage and
duration of treatment for the injectable medicaments is described in detail
in the formulation examples which follow. Since it has been observed that
injecting homeopathic medicaments demonstrate unexpected and significantly
enhanced efficacy when a unipolar magnetic charge is imparted to the
medicament during administration or injection into an acupuncture point, a
device has been developed to enable the administering physician to suitably
charge the medicament. One such device is shown in FIG. 3.
This device consists of a housing 10. Within the housing 10 is an electronic
circuit which delivers a pulsed DC current to the electromagnetic coil 12
with a frequency in the range of about 5 to 10 Hz. The electromagnetic coil
12 is positioned to impart a controlled magnetic charge to core 14. A
syringe or hypodermic needle 16 used to inject the homeopathic medicament
can be positioned in housing 10 such that the point of the needle or syringe
is in close proximity to the end of the core 14 as shown in FIG. 3. The
entire length of the hypodermic needle is magnetized. The end of the needle
which is to enter the skin at the acupuncture point is given the desired
charge. Each molecule of the medicament going down the needle receives a
magnetic charge. Although the charge dissipates when it hits the skin,
during the instant before this happens, the acupuncture point is stimulated
by being bombarded by a series of magnetic impulses.
Another alternative delivery system used is the topical. One particularly
preferred topical system is illustrated in FIG. 2. The topical patch 52 is
made of a porous material such as sintered metal capable of absorbing a
therapeutic amount of homeopathic medicament. The patch 52 has an extended
opening therethrough on the underside of which is tightly fitted a metal
sphere or ball 50 which can readily accept and retain a magnetic charge.
Suitable materials used to prepare the metal sphere or ball 50 include iron,
steel and other ferrous alloys that are magnetically efficient. The patch 52
can then be impregnated with a therapeutic amount of desired homeopathic
medicament. A unipolar magnetic charge is then imparted to the metallic core
50 of patch 52 after it is affixed to a suitable acupuncture point.
In one embodiment, the patch is a dome shaped "donut" shaped
device with a hole in the center as shown in FIG. 2. The patch is formed by
a metal sintering process and is made of a stainless steel alloy that is
virtually non-magnetic. Because it is made of sintered metal, the device is
porous and can be impregnated with a liquid solution of the desired
medication as described later. On the underside of the device, the ball
bearing 50 is press fitted into place within the opening so that it
partially projects below the surface. The ball is made of a ferrous alloy
that is extremely permeable magnetically and will also retain the magnetic
charge. The ball typically is not formed by the sintering process, and it is
not porous so it will not absorb any liquid medication. The patch can be
mounted on a circle of surgical adhesive tape 56, all of which can be
protected by one or more "peel off" strips of release paper 54
similar to the type used with adhesive bandages.
Still another form of administering homeopathic medicaments is orally.
With reference to FIG. 1, this oral device can aptly be described as a
medicinal "lollipop" consisting of a rod portion 40 and a ball or
bulbous portion 42. In one embodiment, the rod 40 is made up of a stainless
steel alloy that is capable of holding a magnetic charge. The ball portion
42 can have an inert core. The ball portion 42 can also be coated with a
homeopathic composition made of ferrous gluconate mixed with sugar to a
dilution in the range of 3.times. to 4.times.. It can then be impregnated
with an alcohol tincture containing the desired homeopathic medicament of
the desired homeopathic dilution. The entire device can be encased in a
sanitary wrapping. To use the "lollipop", the entire device in its
wrapping if desired, is first placed in a suitable electromagnetic field. In
this way, all of the metallic elements of the device are magnetized with one
end of the rod portion being charged with one polarity and the other end of
the rod portion being charged with the opposite polarity. In this manner,
the therapeutic portion of the device having a desired unipolar charge can
influence the ball portion which is placed under the tongue of the patient
in order to contact the acupuncture points in the mouth.
In a specific embodiment, the "handle" or rod 40 of the
"lollipop" is made of a stainless steel or ferrous metal of such
alloy that will readily accept magnetism and will hold the charge well. At
one end, the metal rod 40 is forced into a hole in the ball portion 42
formed of sintered stainless steel. The specific stainless steel alloy used
to form the ball is magnetically transparent so that it will not readily
accept a magnetic charge. The alloy is also porous so that it can be
impregnated with an alcoholic tincture of the desired homeopathic
therapeutic remedy in the desired potency.
The "lollipop" oral delivery device can be positioned under the
tongue in the same way an oral thermometer is used. It will directly
influence three specific acupuncture points. They are: Jin Jin (which
translates as Golden Fluid), Yu-Yeh (Jade Fluid) and Hai Chuen (Sea Spring).
The first two are located on the left and right sides of the vinculum lingua
when the tongue is rolled up. The third point is under the tongue on the
midline about 1/16th inch up from the vinculum lingua.
As a result of this procedure, the acupuncture points in the patient's
mouth, and especially those located under the tongue, are influenced by a
homeopathic medication whose action has been intensified through the use of
the polarized magnetic force.
It is not necessary that the oral device actually contact the acupuncture
points as long as it is placed under the tongue in the general area. The sub
lingual acupuncture points under the tongue will be influenced by the
homeopathic medication with which the ball has been impregnated.
Simultaneously the same sites will also be influenced by the selected
unipolar magnetic force. The portion of the "stick" that has been
charged with the undesired polarity is outside of the mouth during this
entire procedure to prevent any influence of the opposite and undesired
magnetic charge. At the conclusion of the period of treatment, the entire
device is discarded.
Yet another form of administering the homeopathic medicaments is by
auricular measures. An auricular device is illustrated in FIG. 4. In one
such device, a mold 75 is made of a patient's ear by gently pressing
standard mold compound into place so that it takes on the anatomical
contours of the ear and is about 1/8 to 1/4 inches thick. The mold material
is carefully removed so as to preserve the features of the material and is
cured; to the consistency of firm rubber.
Small rods 60 formed of sintered stainless steel, in a ferrous alloy that is
magnetically efficient, are fitted through holes punched in the ear mold.
The holes 65 coincide with the specific acupuncture points in the ear that
are to be influenced. The rods have a rounded point 70 on one end and are
sufficiently long as to extend through the mold and firmly contact the
auricular acupuncture points.
Prior to use, the sintered metal rods are impregnated with the desired
homeopathic medicament as described elsewhere and then dried. They are
positioned in the holes pierced in the molds using forceps to avoid
contamination. The molds are placed back on the patient's ears and then the
desired magnetic charge is induced.
Impregnating with Medicament
In certain preferred embodiments, the sintered metal donut of the patch, and
the ball of the oral lollipop, are porous so that they will absorb an
alcohol tincture of the medicament after which they are dried and packaged.
Merely soaking the metal may not be effective. Instead, in one embodiment,
the sintered metal pieces can be placed into a suitable container with
enough alcohol tincture added to completely cover them. The entire system
goes into a vacuum chamber and a vacuum then pulled producing an intense
surge of tiny bubbles rising to the surface as an indication that, in the
lowered atmospheric pressure, the air entrapped in the interstices of the
sintered metal is being forced out.
After about ten minutes of vacuum, the container and contents are allowed to
return to normal atmosphere. When this happens, the alcohol tincture is
forced into the minute pores of the sintered metal parts. After about ten
minutes the metal pieces absorb all the tincture that they will accept.
Since the air was forced out of the pores of the metal when the container
was under vacuum, it can only be replaced by the tincture when normal
pressure returns because the sintered metal pieces remain completely
submerged in the solution.
In a particularly preferred embodiment, all the medicaments used are at a
30.times. potency. The dilution sequence used to achieve the 30.times.
potency in this embodiment is carried out with 99+% ethanol.
With respect to the transdermal patch, after being impregnated with the
desired medication and then dried, each transdermal patch can be mounted on
a circle of surgical adhesive tape that has a hole punched in the center.
The hole in the top surface of the patch is aligned with the hole in the
adhesive tape. The remainder of the adhesive tape surface can be covered and
protected by one or more "peel-off" strips of release paper of a
similar type to that used in the well known adhesive bandages. The paper
strips are formed with cut-out segments so that the metal donut will project
through.
For convenience, the transdermal patches are packaged in a paper envelope
and supplied in pairs since the units are often applied bilaterally to
acupuncture points on the patient's limbs.
To use the transdermal device, a two-unit package containing patches that
have been impregnated with the appropriate medication is chosen. The
protective backing from each adhesive circle is removed and the unit is
positioned so that the ball bearing on the underside is precisely aligned
with the selected acupuncture point on the patient's skin. The unit is
affixed to the skin by pressing the rim of adhesive tape (the part that
extends beyond the circumference of the donut) firmly against the patient's
skin.
When a magnetic charge is applied, the magnetic force will only influence
the ball bearing since the donut segment of the unit is formed of an alloy
that is not permeable to magnetism. Further, the magnetic charge is applied
in such a manner that the portion of the ball in proximity with one end of
the electromagnetic coil of an electromagnetic stimulating device is given a
charge of one polarity while the bottom portion of the ball that is in
contact with the patient's skin automatically assumes the opposite (and
therapeutically desirable) charge.
In application, the part of the ball bearing that is in contact with the
skin will exert a magnetic force upon the acupuncture point of only the
single desired polarity. The opposite magnetic polarity, the one that, for
the specific medical purpose, is not as desirable in this instance, is on
the opposite (or upper) side of the ball and so does not directly influence
the acupuncture point.
The patient leaves the patches in place on his skin for the period of time
recommended by his physician (usually 4 to 6 hours) before peeling them off
and discarding them.
The following are examples which illustrate embodiments of various aspects
of the invention. The examples are provided to illustrate the scope of the
invention and are not intended to be limiting. Other applications or aspects
of the invention within its broad scope will be apparent to those skilled in
the art.
FORMULATION EXAMPLES
A. Injectable
Example 1
An injectable dosage form of an herb-based homeopathic medicament designated
FNG-11, for the treatment of fungus and yeast infections, having a
homeopathic potency of 30.times. was prepared from an original concentrated
tincture menstruum containing extracts of the herbs Malaleuca alternifolio,
Centella asiatica minor and Tacoma conspicua, extract of citrus seed and
extract of pineal gland in 99+% alcohol. The original concentrated tincture
was diluted to 29.times. potency (10.sup.-29 times the original
concentration) with sterile distilled water. Sufficient ferrous gluconate
solution, a magnetically permeable substance, was added to sterile isotonic
saline to make a homeopathic potency of 4.times.(10.sup.-4). The 29.times.
dilution of the medicament was added to the ferrous gluconate/isotonic
saline solution to prepare the final 30.times. medicament. The purpose of
the ferrous gluconate/isotonic saline solution is to enable the final
medicament to hold a magnetic charge when it is passed through a magnetic
field. Injectable dosage portions of 0.2 cc volumes were set aside as needed
depending upon the number of acupuncture points being used. The formulations
injected were controllably magnetized during administration through the
acupuncture sites as described above.
Example 2
An injectable dosage form of an herb-based homeopathic medicament,
designated HG-9, for the treatment of intestinal parasites, particularly
Giardia lamblia and Entamoeba histolytica, was prepared from an original
concentrated tincture menstruum containing extracts of the herbs Osbeckia
chinensis, Pulsatilla chinensis, Punica granatum, Acalpha australis,
Cephaelis ipecacuanha, Picrasma ailanthoides, Asarum sieboldi, Brucea
javanica, Magnolia officinalis, Artemisia apiacea, Dichroa febrifuga, and
Centella asiatica minor, extract of citrus seed and extract of pineal gland
in 99+% alcohol. The original concentrated tincture was diluted to 29.times.
potency (10.sup.-29 times the original concentration) with sterile distilled
water. Sufficient ferrous gluconate solution, a magnetically permeable
substance, was added to sterile isotonic saline to make a homeopathic
potency of 4.times.(10.sup.-4). The 29.times. dilution of the medicament was
added to the ferrous gluconate/isotonic saline solution to prepare the final
30.times. medicament. The purpose of the ferrous gluconate/isotonic saline
solution is to enable the final medicament to hold a magnetic charge when it
is passed through a magnetic field. Injectable dosage portions of 0.2 cc
volumes were set aside as needed. The formulations injected were
controllably magnetized during administration through the acupuncture sites
as described above.
Example 3
An injectable dosage form of an herb-based homeopathic medicament designated
VR-27, for the treatment of broad spectrum viral infections, having a
homeopathic potency of 30.times. was prepared from an original concentrated
tincture menstruum containing extracts of the herbs Centella asiatica minor,
Pyrrosia lingua, Hypericum perfoliatum, Trichosanthes kirilowii and
Artemisia apiacea, and extract of pineal gland in 99+% alcohol. The original
concentrated tincture was diluted to 29.times. potency (10.sup.-29 times the
original concentration) with sterile distilled water. Sufficient ferrous
gluconate solution, a magnetically permeable substance, was added to sterile
isotonic saline to make a homeopathic potency of 4.times.(10.sup.-4). The
29.times. dilution of the medicament was added to the ferrous gluconate/isotonic
saline solution to prepare the final 30.times. medicament. The purpose of
the ferrous gluconate/isotonic saline solution is to enable the final
medicament to hold a magnetic charge when it is passed through a magnetic
field. Injectable dosage portions of 0.2 cc volumes were set aside as
needed. The formulations injected were controllably magnetized during
administration through the acupuncture sites as described above.
Example 4
An injectable dosage form of an herb-based homeopathic medicament designated
SPN-7, for the treatment of traumatic injury to muscles, tendons, ligaments,
and for the treatment of sprains, was prepared from an original concentrated
tincture menstruum containing extracts of the herbs Panex notoginseng and
Gynura segetum, and Moschus moschiferous and extract of pineal gland in 99+%
alcohol. The original concentrated tincture was diluted to 29.times. potency
(10.sup.-29 times the original concentration) with sterile distilled water.
Sufficient ferrous gluconate solution, a magnetically permeable substance,
was added to sterile isotonic saline to make a homeopathic potency of
4.times.(10.sup.-4). The 29.times. dilution of the medicament was added to
the ferrous gluconate/isotonic saline solution to prepare the final
30.times. medicament. The purpose of the ferrous gluconate/isotonic saline
solution is to enable the final medicament to hold a magnetic charge when it
is passed through a magnetic field. Injectable dosage portions of 0.2 cc
volumes were set aside as needed. The formulations injected were
controllably magnetized during administration through the acupuncture sites
as described above.
Example 5
An injectable dosage form of a homeopathic medicament, designated TYR-10,
for the treatment of hypothyroidism, was prepared from an original
concentrated tincture menstruum containing an extract of thyroid gland, in
99+% alcohol. The original concentrated tincture was diluted to 29.times.
potency (10.sup.-29 times the original concentration) with sterile distilled
water. Sufficient ferrous gluconate solution, a magnetically permeable
substance, was added to sterile isotonic saline to make a homeopathic
potency of 4.times.(10.sup.-4). The 29.times. dilution of the medicament was
added to the ferrous gluconate/isotonic saline solution to prepare the final
30.times. medicament. The purpose of the ferrous gluconate/isotonic saline
solution is to enable the final medicament to hold a magnetic charge when it
is passed through a magnetic field. Injectable dosage portions of 0.2 cc
volumes were set aside as needed. The formulations injected were
controllably magnetized during administration through the acupuncture sites
as described above.
Example 6
An injectable dosage form of an herb-based homeopathic medicament,
designated HRM-4, for the treatment of premenstrual syndrome, menopause,
menstrual discomfort and irregularities, and reproductive hormonal
imbalance, was prepared from an original concentrated tincture menstruum
containing an extract of the herb Angelica sinensis and extract of pineal
gland in 99+% alcohol. The original concentrated tincture was diluted to
29.times. potency (10.sup.-29 times the original concentration) with sterile
distilled water. Sufficient ferrous gluconate solution, a magnetically
permeable substance, was added to sterile isotonic saline to make a
homeopathic potency of 4.times.(10.sup.-4). The 29.times. dilution of the
medicament was added to the ferrous gluconate/isotonic saline solution to
prepare the final 30.times. medicament. The purpose of the ferrous gluconate/isotonic
saline solution is to enable the final medicament to hold a magnetic charge
when it is passed through a magnetic field. Injectable dosage portions of
0.2 cc volumes were set aside as needed. The formulations injected were
controllably magnetized during administration through the acupuncture sites
as described above.
Example 7
An injectable dosage form of a homeopathic medicament, designated HYT-12,
for the treatment of hypothyroidism, was prepared from an original
concentrated tincture menstruum containing a solution of iodine crystals and
extract of pineal gland in 99+% alcohol. The original concentrated tincture
was diluted to 29.times. potency (10.sup.-29 times the original
concentration) with sterile distilled water. Sufficient ferrous gluconate
solution, a magnetically permeable substance, was added to sterile isotonic
saline to make a homeopathic potency of 4.times.(10.sup.-4). The 29.times.
dilution of the medicament was added to the ferrous gluconate/isotonic
saline solution to prepare the final 30.times. medicament. The purpose of
the ferrous gluconate/isotonic saline solution is to enable the final
medicament to hold a magnetic charge when it is passed through a magnetic
field. Injectable dosage portions of 0.2 cc volumes were set aside as
needed. The formulations injected were controllably magnetized during
administration through the acupuncture sites as described above.
Example 8
An injectable dosage form of an herb-based homeopathic medicament for the
treatment of nervous tension, designated RLX-22, was prepared from an
original tincture menstruum containing extracts of the herbs Helianthemum
canadense, Ornithogalum umbellatum, Clematis crispa, Impatiens pallida,
Prunus Cerasus and Valeriana officinalis, and extract of pineal gland in
99+% alcohol. The original concentrated tincture was diluted to 29.times.
potency (10.sup.-29 times the original concentration) with sterile distilled
water. Sufficient ferrous gluconate solution, a magnetically permeable
substance, was added to sterile isotonic saline to make a homeopathic
potency of 4.times.(10.sup.-4). The 29.times. dilution of the medicament was
added to the ferrous gluconate/isotonic saline solution to prepare the final
30.times. medicament. The purpose of the ferrous gluconate/isotonic saline
solution is to enable the final medicament to hold a magnetic charge when it
is passed through a magnetic field. Injectable dosage portions of 0.2 cc
volumes were set aside as needed. The formulations injected were
controllably magnetized during administration through the acupuncture sites
as described above.
Example 9
An injectable dosage from of an herb-based homeopathic medicament,
designated IMM-2, for restoring and strengthening the body's natural immune
system, having a homeopathic potency of 30.times. was prepared from an
original concentrated tincture menstruum containing extracts of the herbs
Panex ginseng, Astragalus membranaceus and Rubia cordifolia, and Snake
venom, extract of thymus gland, and extract of pineal gland in 99+% alcohol.
The original concentrated tincture was diluted to 29.times. potency
(10.sup.-29 times the original concentration) with sterile distilled water.
Sufficient ferrous gluconate solution, a magnetically permeable substance,
was added to sterile isotonic saline to make a homeopathic potency of
4.times.(10.sup.-4). The 29.times. dilution of the medicament was added to
the ferrous gluconate/isotonic saline solution to prepare the final
30.times. medicament. The purpose of the ferrous gluconate/isotonic saline
solution is to enable the final medicament to hold a magnetic charge when it
is passed through a magnetic field. Injectable dosage portions of 0.2 cc
volumes were set aside as needed. The formulations injected were
controllably magnetized during administration through the acupuncture sites
as described above.
Example 10
An injectable dosage form of a homeopathic medicament for the treatment of
hypoglycemia, designated HYG-6, was prepared from an original concentrated
tincture menstruum containing sulfur and vegetable glycerin in 99+% alcohol.
The original concentrated tincture was diluted to 29.times. potency
(10.sup.-29 times the original concentration) with sterile distilled water.
Sufficient ferrous gluccanate solution, a magnetically permeable substance,
was added to sterile isotonic saline to make a homeopathic potency of
4.times.(10.sup.-4). The 29.times. dilution of the medicament was added to
the ferrous gluconate isotonic saline solution to prepare the final
30.times. medicament. The purpose of the ferrous gluconate/isotonic saline
solution is to enable the final medicament to hold a magnetic charge when it
is passed through a magnetic field. Injectable dosage portions of 0.2 cc
volumes were set aside as needed. The formulations injected were
controllably magnetized during administration through the acupuncture sites
as described above.
Example 11
An injectable dosage form of an herb-based homeopathic medicament,
designated INF-16, for the treatment of bacterial infections, particularly
staph and strep, was prepared from an original concentrated tincture
menstruum containing extracts of her herbs Seniccio scandens, Scutellaria
baicalensis, Magnolia officinalis, Lonicera japonica, Andrographis
paniculata, Centella asiatica minor, Leptotaenia multifida and Pupalia
geniculata, and Moschus moschiferous, Cow bezoar, Snake's gall and extract
of pineal gland in 99+% alcohol. The original concentrated tincture was
diluted to 29.times. potency (10.sup.-29 times the original concentration)
with sterile distilled water. Sufficient ferrous gluconate solution, a
magnetically permeable substance, was added to sterile isotonic saline to
make a homeopathic potency of 4.times.(10.sup.-4). The 29.times. dilution of
the medicament was added to the ferrous gluconate/isotonic saline solution
to prepare the final 30.times. medicament. The purpose of the ferrous
gluconate/isotonic saline solution is to enable the final medicament to hold
a magnetic charge when it is passed through a magnetic field. Injectable
dosage portions of 0.2 cc volumes were set aside as needed. The formulations
injected were controllably magnetized during administration through the
acupuncture sites as described above.
Example 12
An injectable dosage from of an herb-based homeopathic medicament,
designated FLU-17, for the treatment of viral infections due to colds and
influenza, particularly rhino-virus, was prepared from an original
concentrated tincture menstruum containing extracts of the herbs Lonicera
confusa, Chrysanthemum indicum, Vitex negundo, Evodia lepta, Ilex asprella,
Baphicacanthus cusia and Centella asiatica minor, and Menthol crystal and
extract of pineal gland in 99+% alcohol. The original concentrated tincture
was diluted to 29.times. potency (10.sup.-29 times the original
concentration) with sterile distilled water. Sufficient ferrous gluconate
solution, a magnetically permeable substance, was added to sterile isotonic
saline to make a homeopathic potency of 4.times.(10.sup.-4). The 29.times.
dilution of the medicament was added to the ferrous gluconate/isotonic
saline solution to prepare the final 30.times. medicament. The purpose of
the ferrous gluconate/isotonic saline solution is to enable the final
medicament to hold a magnetic charge when it is passed through a magnetic
field. Injectable dosage portions of 0.2 cc volumes were set aside as
needed. The formulations injected were controllably magnetized during
administration through the acupuncture sites as described above.
Example 13
An injectable dosage form of an herb-based homeopathic medicament,
designated ALL-5, for the treatment of hayfever and airborne allergies, was
prepared from an original concentrated tincture menstruum containing
extracts of the herbs Gentiana lutea, Citrus aurantium, Tanacetum vulgare,
Cnicus benedictus, Menyanthes trifoliata, Grindelia robusta, Ephedra sinica,
Centipeda minima and Centella asiatica minor, and extract of pineal gland in
99+% alcohol. The original concentrated tincture was diluted to 29.times.
potency (10.sup.-29 times the original concentration) with sterile distilled
water. Sufficient ferrous gluconate solution, a magnetically permeable
substance, was added to sterile isotonic saline to make a homeopathic
potency of 4.times.(10.sup.-4). The 29.times. dilution of the medicament was
added to the ferrous gluconate/isotonic saline solution to prepare the final
30.times. medicament. The purpose of the ferrous gluconate/isotonic saline
solution is to enable the final medicament to hold a magnetic charge when it
is passed through a magnetic field. Injectable dosage portions of 0.2 cc
volumes were set aside as needed. The formulations injected were
controllably magnetized at the time of administration through the
acupuncture sites as described above.
Example 14
An injectable dosage form of an herb-based homeopathic medicament,
designated APN-25, for the treatment of chronic muscular and joint pain,
having a homeopathic potency of 5.times. was prepared from an original
concentrated tincture menstruum containing extracts of the herbs Arnica
Montana, Symphytum officianalis, Pupalia geniculata, Rhus Toxicum, Plantago
asiatica, Causticum (a homeopathic medicament prepared from burnt lime),
Helianthemum canadense, Ornithogalum umbellatum, Clematis crispa, Impatiens
pallida and Prunus Cerasus, and Moschus moschiferous, Cow bezoar, Snake's
gall, Germanium dioxide, and extract of pineal gland in 99+% alcohol. The
original concentrated tincture was diluted to 29.times. potency (10.sup.-29
times the original concentration) with sterile distilled water. Sufficient
ferrous gluconate solution, a magnetically permeable substance, was added to
sterile isotonic saline to make a homeopathic potency of
4.times.(10.sup.-4). The 29.times. dilution of the medicament was added to
the ferrous gluconate/isotonic saline solution to prepare the final
30.times. medicament. The purpose of the ferrous gluconate/isotonic saline
solution is to enable the final medicament to hold a magnetic charge when it
is passed through a magnetic field. Injectable dosage portions of 0.2 cc
volumes were set aside as needed. The formulations injected were
controllably magnetized during administration through the acupuncture sites
as described above.
Example 15
An injectable dosage form of a homeopathic medicament, designated ADR-3, for
the treatment of hypoadrenalism, was prepared from an original concentrated
tincture menstruum containing extract of adrenal gland in 99+% alcohol. The
original concentrated tincture was diluted to 29.times. potency (10.sup.-29
times the original concentration) with sterile distilled water. Sufficient
ferrous gluconate solution, a magnetically permeable substance, was added to
sterile isotonic saline to make a homeopathic potency of
4.times.(10.sup.-4). The 29.times. dilution of the medicament was added to
the ferrous gluconate/isotonic saline solution to prepare the final
30.times. medicament. The purpose of the ferrous gluconate/isotonic saline
solution is to enable the final medicament to hold a magnetic charge when it
is passed through a magnetic field. Injectable dosage portions of 0.2 cc
volumes were set aside as needed. The formulations injected were
controllably magnetized at the time of administration through the
acupuncture sites as described above.
Example 16
An injectable dosage form of a homeopathic medicament, designated CIR-18, to
promote circulation, was prepared from an original concentrated tincture
menstruum containing Germanium dioxide and extract of pineal gland in 99+%
alcohol. The original concentrated tincture was diluted to 29.times. potency
(10.sup.-29 times the original concentration) with sterile distilled water.
Sufficient ferrous gluconate solution, a magnetically permeable substance,
was added to sterile isotonic saline to make a homeopathic potency of
4.times.(10.sup.-4). The 29.times. dilution of the medicament was added to
the ferrous gluconate/isotonic saline solution to prepare the final
30.times. medicament. The purpose of the ferrous gluconate/isotonic saline
solution is to enable the final medicament to hold a magnetic charge when it
is passed through a magnetic field. Injectable dosage portions of 0.2 cc
volumes were set aside as needed. The formulations injected were
controllably magnetized at the site of administration through the
acupuncture sites as described above.
Example 17
An injectable dosage form of an herb-based homeopathic medicament,
designated DTX-28, for the removal of toxicity, was prepared from an
original concentrated tincture menstruum containing extracts of the herbs
Nux vomica, Plantago asiatica, and Carduus marianus, and Germanium dioxide
and extract of pineal gland in 99+% alcohol. The original concentrated
tincture was diluted to 29.times. potency (10.sup.-29 times the original
concentration) with sterile distilled water. Sufficient ferrous gluconate
solution, a magnetically permeable substance, was added to sterile isotonic
saline to make a homeopathic potency of 4.times.(10.sup.-4). The 29.times.
dilution of the medicament was added to the ferrous gluconate/isotonic
saline solution to prepare the final 30.times. medicament. The purpose of
the ferrous gluconate/isotonic saline solution is to enable the final
medicament to hold a magnetic charge when it is passed through a magnetic
field. Injectable dosage portions of 0.2 cc volumes were set aside as
needed. The formulations injected were controllably magnetized during
administration through the acupuncture sites as described above.
Example 18
An injectable dosage form of an herb-based homeopathic medicament,
designated TON-29, for tonification, was prepared from an original
concentrated tincture menstruum containing extracts of the herbs Verbena
hastata, Ephedra sinensis, Turner aphrodisiaca, Sabel serrulata, Hydrocotyle
asiatica, Linosma ovata, Panex ginseng and Echinacea angustifolia, and
extract of pineal gland in 99+% alcohol. The original concentrated tincture
was diluted to 29.times. potency (10.sup.-29 times the original
concentration) with sterile distilled water. Sufficient ferrous gluconate
solution, a magnetically permeable substance, was added to sterile isotonic
saline to make a homeopathic potency of 4.times.(10.sup.-4). The 29.times.
dilution of the medicament was added to the ferrous gluconate/isotonic
saline solution to prepare the final 30.times. medicament. The purpose of
the ferrous gluconate/isotonic saline solution is to enable the final
medicament to hold a magnetic charge when it is passed through a magnetic
field. Injectable dosage portions of 0.2 cc volumes were set aside as
needed. The formulations injected were controllably magnetized during
administration through the acupuncture sites as described above.
Example 19
An injectable dosage form of an herb-based homeopathic medicament,
designated OPT-37, for the treatment of senile macular degeneration, was
prepared from an original concentrated texture menstruum containing extracts
of the herbs Euphrasia officinalis, Pupalia geniculata, Ginkgo biloba,
Vaccinium myrtillus and Hypericum perforiatum, and Moschus moschiferous, Cow
bezoar, Snake's gall and extract of pineal gland in 99+% alcohol. The
original concentrated tincture was diluted to 29.times. potency (10.sup.-29
times the original concentration) with sterile distilled water. Sufficient
ferrous gluconate solution, a magnetically permeable substance, was added to
sterile isotonic saline to make a homeopathic potency of
4.times.(10.sup.-4). The 29.times. dilution of the medicament was added to
the ferrous gluconate/isotonic saline solution to prepare the final
30.times. medicament. The purpose of the ferrous gluconate/isotonic saline
solution is to enable the final medicament to hold a magnetic charge when it
is passed through a magnetic field. Injectable dosage portions of 0.2 cc
volumes were set aside as needed. The formulations injected were
controllably magnetized during administration through the acupuncture sites
as described above.
Example 20
An injectable dosage form of an herb-based homeopathic medicament,
designated LVB-38, for the treatment of liver disfunction, was prepared from
an original concentrated tincture menstruum containing extracts of the herbs
Desmodium stracifolium and Carduus marianus, and extract of pineal gland in
99+% alcohol. The original concentrated tincture was diluted to 29.times.
potency (10.sup.-29 times the original concentration) with sterile distilled
water. Sufficient ferrous gluconate solution, a magnetically permeable
substance, was added to sterile isotonic saline to make a homeopathic
potency of 4.times.(10.sup.-4). The 29.times. dilution of the medicament was
added to the ferrous gluconate/isotonic saline solution to prepare the final
30.times. medicament. The purpose of the ferrous gluconate/isotonic saline
solution is to enable the final medicament to hold a magnetic charge when it
is passed through a magnetic field. Injectable dosage portions of 0.2 cc
volumes were set aside as needed. The formulations injected were
controllably magnetized during administration through the acupuncture sites
as described above.
Example 21
An injectable dosage form of an herb-based homeopathic medicament,
designated TMR-41, for the reduction of tumors, was prepared from the
original concentrated tincture menstruum containing extracts of the herbs
Hypericum japonicum, Prunella vulgaris, Chrysanthemum indicum, Linum
usitatissimum, Ulmus fulva, Nymphaea odorata and Centella asiatica minor,
and extract of pineal gland in 99+% alcohol. The original concentrated
tincture was diluted to 29.times. potency (10.sup.-29 times the original
concentration) with sterile distilled water. Sufficient ferrous gluconate
solution, a magnetically permeable substance, was added to sterile isotonic
saline to make a homeopathic potency of 4.times.(10.sup.-4). The 29.times.
dilution of the medicament was added to the ferrous gluconate/isotonic
saline solution to prepare the final 30.times. medicament. The purpose of
the ferrous gluconate/isotonic saline solution is to enable the final
medicament to hold a magnetic charge when it is passed through a magnetic
field. Injectable dosage portions of 0.2 cc volumes were set aside as
needed. The formulations injected were controllably magnetized during
administration through the acupuncture sites as described above.
Example 22
An injectable dosage form of an herb-based homeopathic medicament,
designated ISC-43, for the treatment of inflammatory conditions and rouleau
cell formation, was prepared from the original concentrated tincture
menstruum containing extracts of the herbs Ilex pubescents, Salvia
multiorrhiza, Andrographis paniculata, Ganoderma japonicum, Pupalia
geniculata and Centella asiatica minor, and Moschus moschiferous, Cow bezoar,
Snake's gall, Germanium dioxide and extract of pineal gland in 99+% alcohol.
The original concentrated tincture was diluted to 29.times. potency
(10.sup.-29 times the original concentration) with sterile distilled water.
Sufficient ferrous gluconate solution, a magnetically permeable substance,
was added to sterile isotonic saline to make a homeopathic potency of
4.times.(10.sup.-4). The 29.times. dilution of the medicament was added to
the ferrous gluconate/isotonic saline solution to prepare the final
30.times. medicament. The purpose of the ferrous gluconate/isotonic saline
solution is to enable the final medicament to hold a magnetic charge when it
is passed through a magnetic field. Injectable dosage portions of 0.2 cc
volumes were set aside as needed. The formulations injected were
controllably magnetized during administration through the acupuncture sites
as described above.
Example 23
An injectable dosage form of an herb-based homeopathic medicament,
designated TBR-44, for the treatment of tuberculosis, was prepared from an
original concentrated tincture menstruum containing extracts of the herbs
Centella asiatica minor and Artemesia apiacea, and Tuberculimum (homeopathic
tincture) and extract of pineal gland in 99+% alcohol. The original
concentrated tincture was diluted to 29.times. potency (10.sup.-29 times the
original concentration) with sterile distilled water. Sufficient ferrous
gluconate solution, a magnetically permeable substance, was added to sterile
isotonic saline to make a homeopathic potency of 4.times.(10.sup.-4). The
29.times. dilution of the medicament was added to the ferrous gluconate/isotonic
saline solution to prepare the final 30.times. medicament. The purpose of
the ferrous gluconate/isotonic saline solution is to enable the final
medicament to hold a magnetic charge when it is passed through a magnetic
field. Injectable dosage portions of 0.2 cc volumes were set aside as
needed. The formulations injected were controllably magnetized during
administration through the acupuncture sites as described above.
B. Oral Form
Example 24
An oral dosage form of the herb-based homeopathic medicament FNG-11, having
the components as in Example 1 above, having a homeopathic potency of
30.times., was prepared in accordance with the procedure described above in
connection with impregnating the lollipop illustrated in FIG. 1. Similarly,
a transdermal dosage form was prepared also as described above.
Example 25
An oral or transdermal dosage form of the herb-based homeopathic medicament
HG-9, having the components as in Example 2, having a homeopathic potency of
30.times., was prepared according to the method of Example 24.
Example 26
An oral or transdermal dosage form of the herb-based homeopathic medicament
VR-27, having the components as in Example 3, having a homeopathic potency
of 30.times., was prepared according to the method of Example 24.
Example 27
An oral or transdermal dosage form of the herb-based homeopathic medicament
SPN-7, having the components as in Example 4, having a homeopathic potency
of 30.times., was prepared according to the method of Example 24.
Example 28
An oral or transdermal dosage form of the homeopathic medicament TYR-10,
having the components as in Example 5, having a homeopathic potency of
30.times., was prepared according to the method of Example 24.
Example 29
An oral or transdermal dosage form of the herb-based homeopathic medicament
HRM-4, having the components as in Example 6, having a homeopathic potency
of 30.times., was prepared according to the method of Example 24.
Example 30
An oral or transdermal dosage form of the homeopathic medicament HYT-12,
having the components as in Example 7, having a homeopathic potency of
30.times., was prepared according to the method of Example 24.
Example 31
An oral or transdermal dosage form of the herb-based homeopathic medicament
RLX-22, having the components as in Example 8, having a homeopathic potency
of 30.times., was prepared according to the method of Example 24.
Example 32
An oral or transdermal dosage form of the herb-based homeopathic medicament
IMM-2, having the components as in Example 9, having a homeopathic potency
of 30.times., was prepared according to the method of Example 24.
Example 33
An oral or transdermal dosage form of the homeopathic medicament HYG-6,
having the components as in Example 10, having a homeopathic potency of
30.times., was prepared according to the method of Example 24.
Example 34
An oral or transdermal dosage form of the herb-based homeopathic medicament
INF-16, having the components as in Example 11, having a homeopathic potency
of 30.times., was prepared according to the method of Example 24.
Example 35
An oral or transdermal dosage form of the herb-based homeopathic medicament
FLU-17, having the components as in Example 12, having a homeopathic potency
of 30.times., was prepared according to the method of Example 24.
Example 36
An oral or transdermal dosage form of the herb-based homeopathic medicament
ALL-5, having the components as in Example 13, having a homeopathic potency
of 30.times., was prepared according to the method of Example 24.
Example 37
An oral or transdermal dosage form of the herb-based homeopathic medicament
APN-25, having the components as in Example 14, having a homeopathic potency
of 30.times., was prepared according to the method of Example 24.
Similarly, oral or transdermal dosage forms of the homeopathic medicaments
as in Examples 15-23, having homeopathic potency of 30.times., were prepared
according to the method of Example 24.
CLINICAL EXAMPLES
AIDS Study Protocol
This study program ran for about 60 weeks comprising the therapeutic phase.
Many patients continued on and participated in the maintenance/prophylaxis
aspect for a total participation of approximately 21/2 years.
Example 38
The treatment regimen in this example utilized a series of specifically
prepared homeopathic medicaments formulated from totally natural botanicals,
minerals and other natural substances, and compounded into highly dilute
(30.times.) homeopathic preparations. Each material was used in triad form:
an injectable, an oral and a transdermal patch.
The list of these special medicaments together with the condition treated is
as follows:
______________________________________
IMM-2 immunity boost
ADR-3 adrenal insufficiency
HG-9 intestinal parasites
TYR-10 thyroid regulation
FNG-11 Candida albicans/other systemic fungus
infections
INF-16 bacterial infection
FLU-17 common cold, flu
CIR-18 circulatory problems
RLX-22 tension and nervousness
APN-25 pain in muscles, tendons, ligaments
VR-27 viral infections
DTX-28 detoxification
TON-29 general tonic
OPT-37 optical problems (Guillain-Barre Syndrome)
LVB-38 liver boost
TMR-41 internal tumors
ISC-43 red cell "clumping"
TBR-44 tuberculosis
______________________________________
COMPONENTS OF TREATMENT
Injection
Homeopathic medicaments were injected into the body at specific acupuncture
points. A 0.2 cc quantity was introduced into each bilateral point with a 30
ga 1/2" needle. For example, the bi-lateral acupuncture point used in
conjunction with VR-27, the anti-viral, is identified on traditional Chinese
charts as TW-5. Other points used with different Homeopathic medicaments for
treating peripheral conditions (as noted below) were ST-36,37; SP-6,9;
LI-11; GB-34, etc. These points are all categorized in Traditional Chinese
Medicine as Command Points and are regarded as being especially effective.
Further, they were selected on the basis of previous trial and error
applications to determine which would be most effective for each specific
malady. Generally, only one pair of points was used to treat each disease
entity. All of the injection sites are located distally to the knee and
elbow. As a result, they were easily located through the use of anatomical
landmarks and present little risk of injury to the patient.
Oral Medication
In addition to being given a series of injections, each patient received
oral (lollipop) homeopathic medication. The therapeutic component consisted
of the same botanical herbs that comprised the injectable medication. This
medication format was also in the highly dilute form traditionally
characteristic of all homeopathic medicaments.
Topical Application
The third treatment modality was a transdermal patch that was taped to the
skin directly over the appropriate acupuncture points. The patches contained
the same formulations in the same highly dilute form as noted above,
compounded into a preparation suitable for this type of application.
Thus, the complete therapeutic modality utilized the interlocking action of homeopathy,
acupuncture, magnetism and herbalism all of which share a long history of
providing effective healing for a wide variety of disease entities. In
application, the homeopathic remedies used within this study were introduced
into the body by injection via the acupuncture points while their action was
reinforced by the parallel use of the same homeopathic medication in oral
form and as a transdermal application.
Stimulation
In each of the three forms, the medications delivered to the body were
magnetically stimulated at the time of introduction. Like the medicaments
themselves, the stimulation was at a homeopathic level.
Treatment of Peripheral Disease Problems
Although this study focused upon the viral component of use of VR-27 as a
therapeutic agent, AIDS cannot be considered to be a single disease entity.
Usually patients present with a variety of subsidiary symptoms closely
associated with the primary viral infection. Commonly seen are such other
viral diseases as herpes, CEBV, CMV and hepatitis. Bacterial infections
include staphylococcus, streptococcus and chlamydia. Fungal infections
include Candida albicans in various manifestations. Parasitical infections
include Entamoeba histolytica and Giardia lamblia. Pneumocyctis carinii and
Syphilis may also be present.
Therefore, although outside the scope of the primary investigation, this
test program also employed a parallel series of homeopathic/acupuncture
treatments for these associated medical conditions where they existed. The
following homeopathic formulations were used for treating the above noted
medical conditions:
______________________________________
FNG-11 (for treatment of fungal infections)
INF-16 (for treatment of bacterial infections)
HG-9 (for treatment of intestinal parasites)
DTX-26 (for detoxifying)
IMM-2 (for encouraging the rebuilding of the immune
system)
______________________________________
In addition, other medicaments selected from the other homeopathic
medicaments described were used where such applications were indicated.
CRITERIA FOR PATIENT INCLUSION AND EXCLUSION
Inclusion
As primary criteria, the first screening was in accordance with the criteria
developed by the Walter Reed Army Hospital to ascertain the presence of
AIDS.
As a prime criteria, the patients had to be HIV positive with a Western Blot
confirmation.
Further screening was on the basis of:
A. Abnormal number of T-4 lymphocytes and abnormal ratio of T-4 to T-8
lymphocytes under 0.6.
B. Age 18 to 60
C. Ability to provide informed consent
D. Ability to keep all appointments
The final group selected included a total of 28 patients. There was a second
evaluation procedure for the participants to identify the presence of other
medical conditions.
Exclusion
The following categories of patients were excluded from the study:
1. Patients on a treatment regimen that utilized highly potent, toxic or
immuno-suppressive drugs such as AZT.
2. Patients receiving medications or supplements of such potency or in
sufficient dosage as to interfere with the activity of the homeopathic
medications.
3. Patients who were already being treated for life threatening diseases of
such severity that, in the opinion of the Administering Physician, they were
terminal.
TREATMENT SCHEDULE FOR PATIENTS IN THE STUDY
For the first 52 weeks, the patients were treated twice a week. During this
period, two medicaments were generally administered at each visit, with
DTX-28 forming a constant along with the regularly scheduled medications.
During this period, treatment was semi-customed to address each patient's
most pressing medical needs with medicines selected from the following
materials:
Anti-Pathogens
VR-27
INF-16
HG-9
FNG-11
According to the patient's pattern of response, the treatment was gradually
broadened to include:
Adjunct Medication
IMM-2
ADR-3
TYR-10
After the first 60 weeks, the treatment schedule was modified to once a
week. As patients began to show favorable response, Anti-Pathogens were only
used on alternate visits with maintenance and prophylaxis medications
filling in the blanks in the schedule.
During this phase, when the need for direct therapeutic action was not as
intense, some additional medications to deal with specific problems were
also used. For example, when there was concern about a possible epidemic of
Influenza, all patients were given two treatments with FLU-17. One patient
was given OPT-37 to deal with his Guillain-Barre Syndrome.
Maintenance Medication
CIR-18
TON-29
RLX-22
ISC-43
TESTS USED WITHIN THE STUDY FOR PATIENTS ACCEPTED AFTER SCREENING
Each patient received a series of weekly, biweekly and monthly lab tests to
provide the tightest possible monitoring of incremental results.
Intake and End-Of-Study Tests
Clinical work-up: Karnofsky score
Laboratory Procedures:
P-24 antigen
Total T-cells+T4/T8 ratio, absolute B-cells
Beta-2-Microblobulin
Neopterin
Circulating Immune Complex, C1Q & C3B
Antibody titers: (IGG & IGM)
Herpes I & II
CMV
EB-VCA
EBV-EA
Hepatitis B diagnostic panel
HIV (quantitative antibody)
CEIA (Candida antibody)
LA-Candida (Candida antigen)
Complete blood count, differential, platelets, hemoglobin and hematocrit
Sedimentation rate
Urethral smear (male) and vaginal smear (female) for Chlamydia
Rectal swab for parasites
Cryptosporidium (stool sample if diarrhea is present)
Candida quantitative culture (mouth lavage)
Gonorrhea culture (urethral or vaginal)
Syphilis serology--RPR, FTA confirmation quantitative
Chem 25 with liver battery
B12-folic acid-iron assays (if hemoglobin below 10 GM/DL) with reticulocyte
count
Urinalysis
Multi-skin tests for DTHS-CMI Multi-Test
Weekly Testing
HIV Antigen (when initially positive)
Antibody titers--(IGG)
Herpes I & II
CMV
EB-VCA
EBV EA
Hepatitis B (to follow chronic carriers)
HIV (quantitative antibody)
CEIA (Candida antibody)
FTA (quantitative)
Chem 25 (with liver battery)
Complete blood count, differential, platelets, hemoglobin, and hematocrit
(if hemoglobin drops below 10 GM/DL, do anemia profile)
Sedimentation rate
Urinalysis
Interval Testing
Candida quantitative culture (mouth lavage)
Total T-cells+T4/T8 ratio, absolute B-cells
Beta 2-Microblobulin
Multi-skin tests for DTHS-CMI Multi-Test
Neopterin
Rectal swab (for intestinal parasites)
TESTING AND RESULTS
I. Analysis of DTHS--Delayed Type Hypersensitivity Skin Tests
As noted in the Merck Manual (fifteenth edition), the T-cell-mediated
portion of the immune system, which is responsible for delayed skin tests
and delayed hypersensitivity, is an important defense against malignant
cells, viral infections, fungal infections and some bacteria.
Delayed Hypersensitivity Skin Tests are valuable screening tests for T-cell
deficiency. The presence of one or more positive delayed skin tests
generally indicates an intact T-cell system.
Many HIV studies regard this measurement as one of the most commonly
monitored parameters of immune functioning.
The favorable direction of the following statistics is in direct contrast
with the usual expectations.
Abstract
Twenty-seven HIV-positive patients enrolled in the study were assessed on
the number and total size of positive reactions to skin test antigens for
cellular hypersensitivity at five points in time. Results indicated
improvement over time with respect to both the number and total size of
positive skin test reactions.
Results and Discussion
Tables 1 and 2 give the mean number of reactions, and the mean size of the
reactions at each time. Trace reactions refer to values of 0.50 mm. The
complete data are provided in Table 3.
TABLE 1
__________________________________________________________________________
MEAN NUMBER OF POSITIVE SKIN REACTIONS
PATIENTS
PATIENTS IN
WITH-
TREATMENT DRAWING
THROUGH BEFORE
ALL FEBRUARY FEBRUARY
PATIENTS
1991 1991
MEAN N MEAN N MEAN N
__________________________________________________________________________
INTAKE 0.26 27
0.36 11
0.19 16
JAN/FEB 1989
0.86 22
0.57 7
1.00 15
AUGUST 1989
2.29 14
2.30 10
2.25 4
FEBRUARY 1990
4.00 12
3.88 8
4.25 4
FEBRUARY 1991
4.55 11
4.55 11
-- --
__________________________________________________________________________
TABLE 2
__________________________________________________________________________
MEAN TOTAL SIZE OF ALL POSITIVE REACTIONS
PATIENTS
PATIENTS IN
WITH-
TREATMENT DRAWING
THROUGH BEFORE
ALL FEBRUARY FEBRUARY
PATIENTS
1991 1991
MEAN N MEAN N MEAN N
__________________________________________________________________________
INTAKE 0.63 27
1.00 11
0.38 16
JAN/FEB 1989
0.95 22
0.29 7
1.27 15
AUGUST 1989
5.49 14
6.17 10
3.80 4
FEBRUARY 1990
13.13 12
12.88 8
13.63 4
FEBRUARY 1991
10.70 11
10.70 11
-- --
__________________________________________________________________________
NOTE: The two patients with intake at February 1989 are included only in
the intake entries (not in the January/February 1990 entries).
TABLE 3
__________________________________________________________________________
DELAYED HYPERSENSITIVITY SKIN TEST (CMI MULTI SKIN TEST) DATA
INTAKE JAN/FEB-89
PATIENT
NOV/DEC-88
10 WEEKS AFTER
# OR AS NOTED
INTAKE TEST
AUG-89 FEB-90
FEB 91
__________________________________________________________________________
1 0/0 2/2T drop-out
2/6 + 1T
2 0/0 3/2.5 + 2T 3/2.7 + 2T
5/20.5
3 0/0 0/0 drop-out
3/12.5
4 2/2T (6.89) 1/1T 4/14.5
5/12.5
5 0/0 2/2T drop-out
6 0/0 0/0 2/1.5 + 1T
4/15.5
4/8
7 1/5 (2/89) 2/9.5 4/16
9 1/1T (2/89) 1/1T 4/10.5
10 0/0 0/0 drop-out
11 0/0 1/1T drop-out
12 0/0 2/2T 2/8 4/13.5
4/12 + 1T
13 1/5 (6/89) 3/12 4/15 6/19.75
14 0/0 (6/89) 4/12 5/14.5
4/2 + 3T
15 0/0 0/0 1/1 absent
2/7 + 1T
16 0/0 0/0 drop-out
17 0/0 0/0 drop-out
18 0/0 0/0 died-(Ap-89)
19 0/0 2/2T drop-out
2/10
20 0/0 0/0 4/9.9 4/10 + 1T
21 0/0 1/1T 3/5.75 + 1T
2/6 3/2.5 + 2T
23 0/0 1/1T 3/3T 4/10
24 0/0 1/1T absent 4/13.5
6/9 + 3T
25 0/0 0/0 drop-out
26 2/5 2/10.5 2/9.5 4/13.5
27 0/0 2/2T drop-out
28 0/0 0/0 drop-out
29 0/0 0/0 1/1T 4/10.5
7/12.5 + 2T
__________________________________________________________________________
NOTE: Patient #8 was an HIV negative partner of participating patient. No
skin tests were done on #8. Patient #22 did not complete initial 12 week
phase of treatment. Patient #22 had only one skin test with 0/0 response.
Absent means that patient was not in attendance at clinic on the day
scheduled for group skin tests.
Numbers to the left of the slash are the number of positive reactions.
Numbers to the right of the slash are the total sizes of all positive
reactions.
A "T" indicates that the size of the reaction is a trace.
There is clearly an increase in the number of positive skin reactions over
the course of the study. Not surprisingly, since the overwhelming majority
of patients had no reactions at intake, there was also an increase in the
total size of all of the positive reactions (p<0.01).
Summary
The following measurements were assessed on the twenty seven HIV-positive
patients enrolled in the study:
1. The number of positive reactions to DTHS skin test antigens for cellular
hypersensitivity at five points in time.
2. The total size of positive reactions to DTHS skin test antigens for
cellular hypersensitivity at five points in time.
The results indicate significant improvement over the course of the study as
indicated by increases in both the number of positive reactions to skin
tests and the total size of those positive reactions.
II. Analysis of Karnofsky Performance Sales
Abstract
Twenty seven HIV-positive patients enrolled in the study were assessed on
the Karnofsky Performance Scale at three points in time. Results indicate
improvement over time with respect to percentage on this clinical
classification system. A sample Karnofsky Performance scale is as follows:
______________________________________
SAMPLE KARNOFSKY PERFORMANCE SCALE
______________________________________
Able to carry on normal
100% Normal, no complaints, no
activity; no special evidence of disease.
care is needed.
90% Able to carry on normal
activity; minor signs of
disease.
80% Normal activity with effort;
some signs or
symptoms of disease
Unable to work; able to
70% Cares for self; unable to
live at home and care carry on normal activity or
for most personal needs;
to do active work.
a varying amount of
assistance is needed.
60% Requires occasional
assistance but is able to
care for most of his needs.
50% Requires considerable
assistance and frequent
medical care.
Unable to care for self;
40% Disabled; requires special
requires equivalent of care and assistance.
institutional or
hospital care; disease
may be progressing
rapidly.
30% Severely disabled;
hospitalization is indicated
although death not imminent.
20% Very sick; hospitalization
necessary; active supportive
treatment is necessary.
10% Moribund; fatal processes
progressing rapidly.
0% Dead.
______________________________________
Results and Discussion
Significant improvement as measured by the Karnofsky score was noted between
intake and March, 1991, for the eleven patients who had completed the
Therapeutic phase of the treatment and were continuing on the
Maintenance/Prophylaxis phases (p=0.0077). All eleven patients had Karnofsky
scores of 100% in March, 1991, (see Tables 4-6). Further examination of the
data indicated that these eleven patients exhibited significant improvement
as early as February/March, 1990, when ten of the eleven had already
achieved Karnofsky scores of 100%, and one patient had a score of 95%.
There was clear evidence of improvement in the eleven patients who continued
in the study through March, 1991. All eleven patients achieved Karnofsky
scores of 100% (ten reached this level as early as February/March, 1990, the
one patient not at 100% at this time was at 95%). The four patients who
completed the Therapeutic phase but did not continue with the full
Maintenance/Prophylaxis phase had achieved scores of 100% by February/March,
1990. These four, as well as the twelve patients who withdrew between April
and June, 1989, had comparable values at intake.
TABLE 4
__________________________________________________________________________
KARNOFSKY SCORE DATA
INTAKE
PATIENT
NOV/DEC 1988
# OR AS NOTED
FEBRUARY/MARCH 1990
MARCH 1991
__________________________________________________________________________
1 90% drop-out
2 90% 100% no maintenance
3 90% 50% drop-out
returned for
follow-up
4 100% (6/90)
100% 100%
5 80% drop-out
6 80% 100% 100%
7 100% (2/89)
100% 100%
9 80% (2/89)
100% some
maintenance
10 90% drop-out
11 90% drop-out
12 85% 100% 100%
13 80% (6/89)
100% 100%
14 90% (6/89)
100% 100%
15 90% 100% 100%
16 80% drop-out
17 90% drop-out
18 80% died - (Ap-89)
19 80% 100% drop-out
returned for
follow-up
20 90% 100% 100%
21 80% 100% 100%
23 90% 100% no maintenance
24 90% 100% 100%
25 80% 60% drop-out
returned for
follow-up
26 80% 100% no maintenance
27 80% drop-out
28 90% drop-out
29 70% 90-100% 100%
__________________________________________________________________________
NOTE: Patient #8 was an HIV negative partner of participating patient.
Patient #22 did not complete initial 12 week phase of treatment.
TABLE 5
__________________________________________________________________________
FREQUENCIES OF KARNOFSKY SCORES
ALL AVAILABLE DATA
KARNOFSKY SCORE
INTAKE FEB/MARCH 1990
MARCH 1991
__________________________________________________________________________
50% 0 1* (5.6%)
0
60% 0 1* (5.6%)
0
70% 1 (3.7%)
0 0
80% 11 (40.7%)
0 0
85% 1 (3.7%)
0 0
90% 12 (44.4%)
0 0
95% 0 1 (5.6%) 0
100% 2 (7.4%)
15* (83.3%)
11 (100%)
__________________________________________________________________________
*Three patients are included in Feb/March 1990 who had withdrawn from the
study prior to this date. These are their scores (50%, 60%, 100%) when
they returned for followup.
TABLE 6
__________________________________________________________________________
FREQUENCIES OF KARNOFSKY SCORES FOR THE ELEVEN
PATIENTS WHO COMPLETED THERAPEUTIC PLUS
MAINTENANCE/PROPHYLAXIS TREATMENT
KARNOFSKY SCORE
INTAKE FEB/MARCH 1990
MARCH 1991
__________________________________________________________________________
70% 1 (9%) 0 0
80% 3 (27%)
0 0
85% 1 (9%) 0 0
90% 4 (36%)
0 0
95% 0 1 (9%) 0
100% 2 (18%)
10 (91%) 11 (100%)
__________________________________________________________________________
Summary
Karnofsky Performance Scores were measured at three points in time. Patients
who completed twelve months of the study reached the score of 100% by
February, 1990. Those patients who continued with the
Maintenance/Prophylaxis treatment maintained their score of 100% through
February, 1991 (the last measurement point).
Those patients who completed the Therapeutic portion of the study scored
between 95% and 100% on the Karnofsky Performance Scales. This is in
contrast to the usual pattern that shows an unremitting decline with the
passage of time.
III. Analysis of Body Weight and Oral Temperature Variability
These two basic Vital Signs were recorded weekly for all patients in the
study. Although simple and easy to take, these criteria are strong
indicators of patient stability or decline.
HIV positive patients are particularly vulnerable to various wasting
diseases as they progress through the stages of AIDS. It was interesting to
note that none of the patients exhibited wasting during any phase of this
treatment.
In HIV patients, oral temperatures tend to be either excessively high or
excessively low (as a result of active bacterial, viral fungal or other
infection). Frequently, the active HIV patient exhibits a sub-normal
temperature (approximately 97.degree. F.) reflecting chronic, low grade
viral infection. In almost all of the patients in this study, temperatures
assumed normal profiles compared to intake values, and remained remarkably
stable for the duration of each patient's treatment.
Abstract
Twenty seven HIV-positive patients enrolled in the study were monitored
weekly for total body weight and oral temperature. Records indicate that no
wasting syndrome was evident at any point in time for any patient.
Temperatures were basically stable from week to week, with a greater
proportion of temperature readings in the normal range as the study
progressed.
Results and Discussion
The temperatures recorded for the patients as a whole are displayed in Table
7.
As shown in Table 7, the percentage of all readings which fell into the
normal range increased steadily over the course of the study. At intake,
29.63% of the patients had normal temperatures. Between Weeks 1-12, the
percentage rose to 50.18%. Weeks 13-24 show 61.40%, and Weeks 25-36 show
60.95%. After Week 37, the number of normal temperature readings shows
another sizeable increase to 79.48%.
It should be pointed out that no wasting syndrome was experienced by any of
the patients in the Study. In fact, records showed that 10 patients out of
27 (37.03%) actually gained weight during their participation in the
Project.
TABLE 7
__________________________________________________________________________
FREQUENCIES OF TEMPERATURE READINGS
TEMPERATURE
INTAKE
WEEKS 1-12
WEEKS 13-24
WEEKS 25-36
WEEKS 37+
__________________________________________________________________________
>100 1 3 3 0 1
(VERY HIGH)
(3.70%)
(1.10%)
(1.10%) (0.00%) (0.85%)
99.1-100 1 13 13 4 2
(HIGH) (3.70%)
(4.76%)
(4.76%) (3.81%) (2.71%)
98.2-99.0 8 137 167 64 93
(NORMAL) (29.63%)
(50.18%)
(61.40%)
(60.95%)
(79.48%)
97.0-98.1 17 119 89 37 21
(LOW) (62.96%)
(43.59%)
(32.72%)
(35.24%)
(17.95%)
<97.0 0 1* 0 0 0
(VERY LOW)
(0.00%)
(0.37%)
(0.00%) (0.00%) (0.00%)
__________________________________________________________________________
*The one reading of "VERY LOW" represents a patient whose temperature was
recorded as 94.8. It seems likely that this is a data entry error.
However, it has been included in the table.
Summary
Both weights and temperatures were stable from week to week. The proportion
of recorded temperatures in the normal range gradually became higher as the
study progressed. Conversely, the proportion of chronically low temperatures
decreased.
IV. Statistical Analysis Of Symptom Data Generated By Patients Who Completed
Treatment And Maintenance Phases Of The Study
Abstract
Twenty-seven HIV-positive patients enrolled in the study were evaluated for
the presence or absence of a series of forty symptoms presented from intake
to two later points in time. Six scales were constructed as subsets of the
original forty symptoms examined plus a TOTAL compilation. While borderline
improvement was noted for one of the scales, significant improvement was
evident for the other five scales. The TOTAL category (evaluation of overall
number of symptoms present) also showed marked and progressive improvement.
The attached Tables 8 and 9 list the individual symptoms that have been
grouped as follows:
Group 5 (symptoms most related to HIV disease progression)
Group 3 (symptoms moderately related to HIV disease progression)
Group 1 (symptoms mildly related to HIV disease progression)
The additional scales were:
FUNGAL (symptoms due to fungal infection)
QUALITY (daily quality of life)
WELL BEING (sense of well being)
TOTAL (all symptoms)
Results and Discussion
The results indicate that patients improved from intake to November, 1990.
The mean number of symptoms per patient was reduced from 8.08 at intake to
1.73 in November (a decrease of 79%). This decrease was consistent across
all of the scales. Group 5 symptoms decreased 87%, Group 3 symptoms
decreased 67%, Group 1 symptoms decreased 87%, FUNGAL symptoms decreased
85%, WELL BEING symptoms decreased 85% and QUALITY symptoms decreased 76%.
(See Table 10).
Summary
Data consisting of the presence or absence of a series of forty symptoms
were collected on twelve patients infected with HIV at three points in time.
The results indicate clear improvement from intake to November, 1990, as
measured by the number of symptoms present. With the exception of one scale,
"Sense of Well Being" in which improvement was only borderline,
the other five scales all provide evidence indicative of significant
improvement.
TABLE 8
__________________________________________________________________________
TOTAL NUMBER OF SYMPTOMS AND
MEAN NUMBER OF SYMPTOMS PER PATIENT*
INTAKE MAY NOVEMBER
(NOV-DEC 1988)
1990 1990
__________________________________________________________________________
TOTAL # OF SYMPTOMS
97 (8.08) 47 (3.92)
19 (1.73)
GROUP 5 SYMPTOMS 34 (2.83) 10 (0.83)
4 (0.36)
(SYMPTOMS MOST RELATED
TO HIV PROGRESSION)
BURNING MOUTH (THRUSH)
1 1 0
SHORTNESS OF BREATH
3 0 0
DIARRHEA 2 0 0
LACK OF APPETITE 1 0 0
BONE/MUSCLE ACHE 5 2 1
NIGHT SWEATS 0 2 0
ARTHRITIS-LIKE ACHES
1 0 0
TROUBLE BREATHING 1 0 0
FATIGUE 7 2 1
ATHLETE'S FOOT 4 1 1
JOCK ITCH 2 0 0
FINGER/TOE NAIL FUNGUS
3 2 1
LACK OF SEXUAL DESIRE
2 0 0
BURN/ITCH/GROIN/SCROTUM
1 0 0
VAGINAL ITCH 1 0 0
VAGINAL BURNING 0 0 0
VAGINAL SORENESS 0 0 0
GROUP 3 SYMPTOMS 39 (3.25) 24 (2.00)
12 (1.08)
(SYMPTOMS MODERATELY
RELATED TO HIV
PROGRESSION)
HEADACHE 4 2 1
COUGH 3 0 0
CLOUDY EYESIGHT 3 2 1
SORE THROAT 1 0 0
BLEEDING GUMS 3 2 1
HAIR LOSS 1 0 0
EYE FOCUS PROBLEMS
5 1 0
TROUBLE SLEEPING 3 2 1
BUMPS THAT ITCH 3 2 0
SWOLLEN GLANDS 5 5 5
UNFRESHED SLEEP 5 5 3
DEPRESSION 3 3 0
_______________________________________________